oleozon

Silsaa ja sienien aiheuttamia ihottumia vastaan:
http://archives.foodsafetynetwork.ca/fsnet/2001/4-2001/fs-04-26-01-01.txt

OZONIZED SUNFLOWER OIL SHOWS VALUABLE ACTIVITY AGAINST
MYCOBACTERIA
April 26, 2001
TB & Outbreaks Week via NewsEdge Corporation
N.R. Saltmarsh
Sunflower oil ozonized by an ozone generator shows valuable activity against
mycobacteria and other bacterial species, say researchers working in Italy.
L.A. Sechi and colleagues tested ozonized sunflower oil (Oleozon) against
mycobacteria, staphylococci, streptococci, enterococci, Pseudomonas spp.,
and Escherichia coli isolated from different sites.
Oleozon showed a minimum inhibitory concentration (MIC) against all strains
of mycobacteria tested of 1.18 to 9.5 mg/ml, reported Sechi and team. They
noted that Oleozon showed activity against all bacteria tested, but was most
potent against mycobacteria.
"The wide availability of sunflower oil makes Oleozon a competitive
antimicrobial agent," concluded Sechi et al. "These results should prompt
the
setting up of some clinical trials to compare Oleozon with other
antimicrobial
agents."
A paper describing their study was published in the Journal of Applied
Microbiology ("Antibacterial activity of ozonized sunflower oil (Oleozon),"
J
Applied Microbiol, 2001;90(2):279-284).
The corresponding author for this study is L.A. Sechi, Univ. Sassari,
Dipartimento Sci. Biomed., Sez. Microbiol. Sperimentale & Clin., Viale S.
Pietro
43-B, I-07100 Sassari, Italy.
Key points reported in this study include:
· Researchers evaluated the antimicrobial effect of Oleozon on different
bacterial species isolated from different sites
· Oleozon showed valuable activity against all bacterial strains tested,
especially mycobacteria, with an MIC ranging from 1.18 to 9.5 mg ml
· Oleozon shows potential, particularly given its wide availability, and
should be
compared to other antimicrobial agents in future trials
This article was prepared by TB & Outbreaks Week editors from staff and
other
reports.
0573
Äänestä

Muut lukivat myös

Vastaukset

Vanhimmat

Ei vielä vastauksia

Aloittaja odottaa vastauksia. Kerro oma näkemyksesi ensimmäisenä.

Kommentoi aloitusta


googlella kirjoitti:

Silsaa ja sienien aiheuttamia ihottumia vastaan:
http://archives.foodsafetynetwork.ca/fsnet/2001/4-2001/fs-04-26-01-01.txt

OZONIZED SUNFLOWER OIL SHOWS VALUABLE ACTIVITY AGAINST
MYCOBACTERIA
April 26, 2001
TB & Outbreaks Week via NewsEdge Corporation
N.R. Saltmarsh
Sunflower oil ozonized by an ozone generator shows valuable activity against
mycobacteria and other bacterial species, say researchers working in Italy.
L.A. Sechi and colleagues tested ozonized sunflower oil (Oleozon) against
mycobacteria, staphylococci, streptococci, enterococci, Pseudomonas spp.,
and Escherichia coli isolated from different sites.
Oleozon showed a minimum inhibitory concentration (MIC) against all strains
of mycobacteria tested of 1.18 to 9.5 mg/ml, reported Sechi and team. They
noted that Oleozon showed activity against all bacteria tested, but was most
potent against mycobacteria.
"The wide availability of sunflower oil makes Oleozon a competitive
antimicrobial agent," concluded Sechi et al. "These results should prompt
the
setting up of some clinical trials to compare Oleozon with other
antimicrobial
agents."
A paper describing their study was published in the Journal of Applied
Microbiology ("Antibacterial activity of ozonized sunflower oil (Oleozon),"
J
Applied Microbiol, 2001;90(2):279-284).
The corresponding author for this study is L.A. Sechi, Univ. Sassari,
Dipartimento Sci. Biomed., Sez. Microbiol. Sperimentale & Clin., Viale S.
Pietro
43-B, I-07100 Sassari, Italy.
Key points reported in this study include:
· Researchers evaluated the antimicrobial effect of Oleozon on different
bacterial species isolated from different sites
· Oleozon showed valuable activity against all bacterial strains tested,
especially mycobacteria, with an MIC ranging from 1.18 to 9.5 mg ml
· Oleozon shows potential, particularly given its wide availability, and
should be
compared to other antimicrobial agents in future trials
This article was prepared by TB & Outbreaks Week editors from staff and
other
reports.

Anonyymi
5000

Ilmoita asiaton sisältö

  • Sisältää materiaalia, joka on loukkaavaa, herjaavaa, rasistista, uhkailevaa tai ahdistelevaa.

  • Materiaali sisältää nimiä, yhteystietoja tai muita henkilökohtaisia tietoja. Julkisuuden henkilöistä, julkisissa viroissa toimivista ihmisistä sekä yritysten vastuuhenkilöistä saa keskustella työhön liittyen. Myös yksityiselämään liittyvistä asioista voi keskustella siltä osin, kuin niistä on julkisesti kerrottu.

  • Sisältää lapsille haitallista tai heiltä kiellettyä materiaalia. Seksuaalinen sisältö on sallittua aiheeseen tarkoitetuilla palstoilla, joiden ikäraja on 18 vuotta.

  • Lainvastaista sisältöä voi olla mm. yksityiselämää loukkaavan tiedon levitys, kiihottaminen kansanryhmää vastaan, laiton uhkaaminen, alaikäisiin liittyvä seksuaalinen sisältö/grooming, petokset, identiteettivarkaudet, kunnianloukkaukset ja tekijänoikeusrikkomukset.

  • Sisältö ei liity palstan tai keskusteluketjun aiheeseen.

  • Viesti ei ole suomea tai ruotsia (pl. International Forums), se sisältää mainontaa, se sisältää tekijänoikeuksin suojattua materiaalia, se on massapostitus tai jokin muu syy.

Jaa keskustelu